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Abstract 
Hidradenitis suppurativa is a chronic disease that affects the apocrine gland-bearing 
regions of the body. The etiology of this disorder is poorly understood, but most likely is 
a complex process involving follicular apocrine occlusion with subsequent perifolliculitis. 
Many treatment options have been reported with varying degrees of success, including 
topical and oral therapy and surgical procedures. Recently, TNF-α antagonists have been 
reported as effective therapy in a few patients. We report here a patient who initially 
responded to infliximab but developed an infusion reaction to this medication. After 
subsequent treatment with adalimumab, the patient’s disease improved dramatically 
and has been maintained under excellent control for over 15 months. We propose that 
TNF-α inhibitors, particularly monoclonal antibody based agents, are a viable treatment 
option in patients with severe, recalcitrant HS and that a patient may be safely and 
successfully treated with the fully human monoclonal antibody adalimumab in cases in 
which the chimeric monoclonal antibody infliximab therapy is not tolerated. 
 
Introduction 
Hidradenitis suppurativa (HS) is a chronic skin disease characterized by abscess and 
sinus tract formation in areas of the body with apocrine sweat glands. The exact 
pathophysiology of HS is still not understood but it is likely that a multitude of factors, 
including genetics, bacterial infection, hormones, inflammation, mechanical occlusion, 
and possibly even smoking, play a role [1]. HS tends to start after puberty, persists for 
years and may worsen over time. The reported prevalence is between 0.25–5%. It is more 
common in females and African-Americans, and it has been associated with Crohn’s 
disease and arthropathy. Furthermore, 38% of patients presenting with HS have a positive  
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family history for the disease [2]. A multitude of treatment options are available, 
including topical and systemic agents, surgery, and recently TNF-α inhibitors. 
Case Report 
A 47-year-old white female with a 10-year history of HS was referred for the treatment of painful 
nodules and purulent draining sinuses in her axillary, inguinal, and mammary areas. Our patient is thin 
and otherwise healthy. Previous treatment for her HS included combinations of numerous topical 
antibiotics including clindamycin and chlorhexidine scrubs, oral antibiotics including doxycycline, 
intralesional triamcinolone, isotretinoin, and systemic prednisone. In addition, multiple surgical 
procedures, including excision and grafting of the affected skin, were performed, ultimately all with 
unsuccessful outcomes. After failure of these treatments, the patient began therapy with infliximab and 
had near complete clearing of her active disease. However, within 15 months of infliximab therapy, the 
medication’s efficacy diminished to 10 days per infusion. At 18 months, the patient developed a severe 
infusion reaction with urticaria and the medication was discontinued. 
Several weeks after discontinuation of infliximab, physical exam revealed the return of her disease 
(fig. 1a). We sought a treatment regimen that would effectively treat her disease and minimize adverse 
effects. Because of her previous successful treatment with a TNF-α inhibitor, we proposed a trial of 
another biologic agent, adalimumab.  
Before treatment with adalimumab, the patient had a complete blood count, liver function tests, a 
purified protein derivative test, chest radiography, and hepatitis B, hepatitis C, and human 
immunodeficiency virus antibody panel, which showed no abnormalities. She had no personal history 
of malignancy. The patient was begun on 40-mg injections of adalimumab every other week. The 
patient was re-evaluated 3 months into her treatment and her HS was significantly improved with a 
decrease in drainage from old lesions and a decrease in the formation of new lesions. Over the past 15 
months of adalimumab therapy, the patient has remained clear except for the development of a few 
small nodules which were effectively managed with intralesional triamcinolone (fig. 1b). 
Discussion 
HS represents a spectrum of disease ranging from tender papules with minimal pain to 
deep-seated nodules, which can serve as a nidus for recurrent systemic infection, fistula 
formation with internal organs such as the bladder, or even squamous cell carcinoma [3]. 
The condition was classically thought to occur when blocked apocrine glands forced 
perspiration and bacteria into surrounding tissue, causing subcutaneous inflammation 
and infection. More recent studies have indicated that HS is caused by follicular occlusion 
first, which then occludes the apocrine glands and causes perifolliculitis [4]. 
In 10 out of their 12 histologic samples of HS, Yu and Cook identified squamous 
epithelium-lined structures, which likely represent abnormally dilated hair follicles, in the 
form of cysts or sinuses within the dermis; inflammation of the apocrine glands was seen 
in only 4 out of 12 samples. In these samples the inflammation was also seen surrounding 
eccrine glands, hair follicles, and the epithelium-lined structures, suggesting that apocrine 
gland inflammation is a secondary phenomenon rather than an initiating event [1]. In 60 
specimens studied by Jemec and Hansen, only 12% contained apocrine gland involvement 
[5]. In a 2005 review by Sellheyer and Krahl, serial histologic specimens demonstrated 
progression of HS from perifollicular hyperkeratosis and subsequent comedo 
development to rupture of the follicular infundibulum which caused local dermal 
inflammation [4]. Over time, it is believed that these granulomatous infiltrates cause the 
formation of the abscesses seen in HS.  
The critical role of follicular occlusion was also highlighted by a comparison of 
specimens from affected individuals and controls that demonstrated follicular occlusion  
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only in the axillary and inguinal skin of all affected individuals [6]. Further support for a 
primary folliculitis was found in another study that demonstrated an infundibulum 
centered T-cell rich infiltrate in early lesions. The T cells were chiefly HLA-DR positive 
with a low percentage of Leu-8 positive lymphocytes [7]. Therefore, HS is likely an 
inflammatory disease of the hair follicle that can be included among other diseases of 
follicular occlusion and should be considered a part of the follicular occlusion tetrad [8]. 
A number of treatment options are currently used to treat HS (table 1) [9, 10]). First-
line measures include weight loss, smoking cessation, and hygiene measures. If these 
measures fail, subsequent therapy includes the use of long-term topical and systemic 
antibiotics, hormonal treatment, intralesional corticosteroids, systemic retinoids, and 
surgical procedures. For many patients, the disease is characterized by recurrences 
regardless of the treatment modality used. Therefore, it is critical that the benefits of these 
therapies must be weighed against potential adverse effects.  
Given the important role of TNF-α in granuloma formation, we considered the 
possibility that adalimumab may be an effective treatment for HS. Our patient enjoyed 
marked improvement early in the treatment of her HS with infliximab, but this response 
was not sustained over months. Since 25% of the sequence of infliximab is mouse-derived, 
it has been associated with the development of antibodies against the murine portion of 
the antibody, which may lead to infusion reactions and loss of efficacy [11]. In studies of 
patients with Crohn’s disease, adalimumab has been shown to be effective in patients who 
lost response to infliximab [12]. Adalimumab is a fully humanized anti-TNF-α antibody. 
It has a high specificity and affinity for TNF-α. Adalimumab was first tested in 1997 for 
rheumatoid arthritis and was developed to have low immunogenicity, avoiding the need 
for concomitant administration of immunosuppressants such as methotrexate.  
Despite its benefit in the treatment of recalcitrant HS, adalimumab does have known 
associated risks. The drug carries warnings regarding reactivation of latent TB and 
invasive fungal infections, both of which have been reported in patients treated with 
adalimumab. Other adverse events reported following all TNF-α antagonist treatment 
include lupus-like syndromes [13], demyelinating disorders [14], and congestive heart 
failure [15]. Controversy exists as to the risk of lymphoma associated with adalimumab 
use [16, 17]. In addition, the cost and the lack of long-term efficacy data should be 
considered before using adalimumab to treat HS. 
Considerable interest exists in the use of biologic agents for HS. Their use in HS was 
pioneered with intravenous infliximab in a female patient treated for Crohn’s disease who 
had concomitant HS. The patient had significant reduction in her HS within a few 
treatments with infliximab [18]. Our patient shared this similar success with infliximab 
initially, before its efficacy diminished. In contrast, a recent open-label study of etanercept 
in 15 patients failed to show a statistically significant improvement in disease control [19]. 
The use of adalimumab in HS is limited thus far to a few case reports and small case 
series in patients with refractory disease (table 2) [20–25]). Due to the role of 
inflammation in HS, biologic therapy will likely play a role in the future treatment of 
refractory HS. The seemingly disparate efficacy of the TNF-α receptor fusion protein 
etanercept and the monoclonal antibodies infliximab and adalimumab in treating HS 
suggest that there may be a difference in mechanism due to the structural differences in 
these biologic agents. One study showed that in a mouse model of pulmonary 
tuberculosis, a monoclonal anti-TNF-α antibody was better able to penetrate into 
granulomas than a TNF-α receptor fusion protein [26]. Given the granulomatous nature 
of HS, this finding may explain the possible superiority of the monoclonal antibodies in  
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treating this condition. However, more rigorous prospective trials are necessary to fully 
determine the efficacy of these biologics in treating HS. 
 
 
 
Table 1. Treatment of hidradenitis suppurativa 
Treatment Level  of 
evidence* 
Efficacy 
Local therapy  
Clindamycin   1 
Intralesional steroids  3 
Antimicrobial washes  3 
 
superior to placebo 
effective 
unknown 
Systemic therapy  
Tetracycline
# 1 
Cyproterone 
 
1; 2 
Finasteride 2 
Isotretinoin 2 
Clindamycin + rifampicin  2 
Zinc salts  2 
Etretinate 3 
Acitretin 3 
Cyclosporine 3 
Dapsone 2 
Systemic steroids  3 
Methotrexate 3 
TNF-α inhibitors  2 
 
equivalent to topical clindamycin 
no effect over estrogen therapy; 
possibly effective over antibiotics 
partial efficacy 
limited efficacy 
effective 
effective 
effective 
effective 
effective 
effective 
possibly effective 
weak to none  
effective in some patients 
Physical modalities  
Incision/drainage  
Surgical treatment  2 
Radiation treatment   
CO2 laser  2 
Botulinum toxin  3 
Photodynamic therapy  2 
 
effective for pain only 
effective (for severe disease only) 
possibly effective 
effective (compared to surgery) 
effective 
not effective 
1 = RCT; 2 = retrospective, case-control, small therapeutic trials, case series; 3 = 
case report, common practice. * When discernible; 
#  or related drug. 
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Table 2. Reports of treatment of hidradenitis suppurativa with adalimumab 
Authors Type 
of study 
Number 
of 
patients 
Treatment   Duration of 
disease 
Duration 
of 
response* 
Adverse events 
Harde and 
Mrowietz 
case 
report 
1  80 mg SC ×1, 
then 40 mg QW 
12 years  6 months  none 
Yamauchi 
and Mau 
case 
series 
3 range: 
40 mg EOW 
to 40 mg QW 
range: 
3 months to 
5 years 
1 year  none 
Moul and 
Korman 
case 
report 
1  40 mg EOW  20 years  4 months  none 
Scheinfeld case 
report 
1  40 mg EOW, 
then QW 
15 years  not reported  none reported 
Blanco 
et al. 
case 
series 
6  40 mg EOW, 
up to QW prn 
22.5 years 
(mean) 
21.5 months 
(mean); 
range: 13–29 
mild injection site 
pain; facial cellulitis
in 1 patient 
Sotiriou 
et al. 
case 
series 
3  40 mg EOW  4.3 (mean)  discontinued 
treatment at 3 
months in all 
patients 
none reported 
* At time of publication. 
 
 
 
 
Fig. 1. a Pre-treatment. b After 15 months. 
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